Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s disease, diabetic neuropathy, glaucoma, viral infections, chemotherapy-induced peripheral neuropathy and stroke, among others.
Mira Pharmaceuticals Inc. has reported continued progress toward IND-enabling studies of its two lead preclinical programs, MIRA-55, an investigational oral nonopioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders.
TSC Alliance and Apertura Gene Therapy LLC have announced progress in their collaboration to advance gene therapies to treat tuberous sclerosis complex (TSC) with the completion of a preclinical pilot study evaluating an AAV gene therapy approach for TSC1.
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and disease.
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor agonists potentially useful for the treatment of schizophrenia, depression, Parkinson’s and Alzheimer’s disease.
Researchers from Aglaeapharma Inc. and Alpherabio LLC reported the discovery and preclinical characterization of CC-10137, a nonopioid α2A-adrenergic receptor (α2AAR) agonist designed for peripheral activity.
Shape Therapeutics Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance SHP-201, the company’s lead gene therapy candidate.
Suven Life Sciences Ltd. has reported new muscarinic acetylcholine M4 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of schizophrenia, Alzheimer’s disease, Parkinson’s disease, depression, bipolar disorders, Huntington’s disease, attention deficit hyperactivity disorder and pain, among others.
Chengdu Shibeikang Biological Medicine Technology Co. Ltd. has patented new trichloroethanol derivatives potentially useful for the treatment of sleep disorders, anxiety disorders and convulsions.
Biomarin Pharmaceutical Inc. and the n-Lorem Foundation have signed a strategic collaboration and global exclusive license agreement to develop a first-in-disease antisense oligonucleotide (ASO) medicine for people with ReNU syndrome, a rare neurodevelopmental condition caused by variants in the RNU4-2 gene.
RSS
